JPRN-jRCT2080223862已完成2 期
A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label)
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participants with histological diagnosis of B-cell non-Hodgkin's lymphoma (NHL) as follows:
- •--Cohort 1: Follicular lymphoma (FL)
- •--Cohort 2: Diffuse large B-cell lymphoma (including primary mediastinal B-cell lymphoma and transformed FL)
- •-Participants who have confirmed EZH2 gene mutation of tumor in central laboratory
- •-Participants who have measurable disease
- •-Participants who had previous therapy with systemic chemotherapy and/or antibody therapy and for which no standard therapy exists
- •-Participants who had progressive disease or did not have response (complete response or partial response) in previous systemic therapy, or relapsed or progressed after previous systemic therapy
- •-Participants with Eastern Cooperative Oncology Group performance status of 0 to 1
- •-Participants with life expectancy of >= 3 months from starting study drug administration
- •-Participants with adequate renal, liver, and bone marrow function
- •-Male and female participants >= 20 years of age at the time of informed consent
- •-Participants who has provided written consent to participate in the study
排除标准
- •-Participants with prior exposure to EZH2 inhibitor
- •-Participants with a history or a presence of central nerves invasion
- •-Participants with malignant pleural effusion, cardiac effusion, or ascites retention
- •-Participants with allogeneic stem cell transplantation
- •-Participants with medical need for the continued use of potent inhibitors of Cytochrome P450 3A (CYP3A)or potent inducer of CYP3A (including St. John's wort)
- •-Participants with significant cardiovascular impairment
- •-Participants with prolongation of corrected QT interval using Fridericia's formula to > 480 milliseconds (msec)
- •-Participants with venous thrombosis or pulmonary embolism within the last 3 months before starting study drug
- •-Participants with complications of hepatic cirrhosis, interstitial pneumonia or pulmonary fibrosis
- •-Participants with active infection requiring systemic therapy
- •-Women of childbearing potential or man of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception for periods from before informed consent to during the clinical study and 30 days later (for males 90 days later) from last administration of study drug
研究者
相似试验
已完成
2 期
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationRelapsed or Refractory B-cell Non-Hodgkin's LymphomaNCT03456726Eisai Co., Ltd.20
招募中
2 期
CCH2107/MK012 trialEpithelioid SarcomaLoss of INI1 protein, Epithelioid SarcomaD012509JPRN-jRCT2031220523Yonemori Kan15
进行中（未招募）
1 期
Study of tazemetostat in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients or high risk Follicular Lymphoma (FL) patientstreated by R-CHOPnewly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL)MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 24.0Level: LLTClassification code 10029473Term: Nodular (follicular) lymphomaSystem Organ Class: 100000004864EUCTR2016-001499-31-BEYSARC201
进行中（未招募）
1 期
Study of tazemetostat in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOPEUCTR2016-001499-31-FRYSARC133
进行中（未招募）
1 期
A Study on the Effect of Tazemetostat (study drug) in Pediatric Subjects withwith relapsed or refractory Tumors or Synovial SarcomaAtypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features.Epithelioid sarcoma, Epithelioid malignant peripheral nerve sheath tumor, Extraskeletal myxoid chondrosarcoma, Myoepithelial carcinoma, Renal medullary carcinoma, Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approval, Synovial Sarcoma with a SS18-SSX rearrangementMedDRA version: 21.1Level: LLTClassification code 10064886Term: Renal medullary carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10065870Term: Atypical teratoid/rhabdoid tumor of CNSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10073134Term: Extraskeletal myxoid chondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10073335Term: Rhabdoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074121Term: Rhabdoid tumor of the kidneySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10015100Term: Epithelioid sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002468-18-GBEpizyme, Inc.120